<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153367">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103440</url>
  </required_header>
  <id_info>
    <org_study_id>GCO-07-0200</org_study_id>
    <nct_id>NCT01103440</nct_id>
  </id_info>
  <brief_title>Aspirin Resistance and Percutaneous Coronary Intervention (PCI)</brief_title>
  <acronym>RESIST</acronym>
  <official_title>A Randomized, Pilot, Single-center Study, Investigator-Initiated Study to Look at an Aggressive Therapeutic Approach in Aspirin Resistant Patients Comparing to Standard for Patient Undergoing Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate if aggressive antiplatelet therapy would reduce
      ischemic events in aspirin (ASA) resistant patients after percutaneous coronary intervention
      (PCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is the first US based randomized double blinded prospective study using triple
      antiplatelet therapy and double dose plavix maintenance dose in aspirin resistant patients
      undergoing elective PCI through femoral access. The primary outcome of this study is an
      elevation of cardiac enzymes within 24 hours after the PCI with a secondary outcome of a
      composite of major adverse cardiac events of death, MI, stent thrombosis and urgent
      revascularization and bleeding up to 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Elevation of Cardiac Enzyme</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event</measure>
    <time_frame>30 days</time_frame>
    <description>Death, MI, Stent Thrombosis, Urgent Revascularization, Bleeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Stable Angina</condition>
  <arm_group>
    <arm_group_label>Conventional Strategy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient receive 325 mg ASA orally and loading does of 600mg Clopidogrel at time of procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aggressive Strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient receive 325mg ASA orally and loading does of 600mg Clopidogrel at time of procedure with addition of IV GP IIb/IIIa inhibitor bolus intra procedurally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Glycoprotein inhibitor + ASA, Clopidogrel</intervention_name>
    <description>IV Glycoprotein IIb/IIIa inhibitor bolus intra procedurally</description>
    <arm_group_label>Aggressive Strategy</arm_group_label>
    <other_name>Cangrelor</other_name>
    <other_name>Abciximab</other_name>
    <other_name>Eptifibatide</other_name>
    <other_name>Tirofiban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiplatelet Therapy (ASA, Clopidogrel)</intervention_name>
    <description>Standard antiplatelet PCI treatment</description>
    <arm_group_label>Conventional Strategy</arm_group_label>
    <other_name>Thienopyridines</other_name>
    <other_name>Ticlopidine</other_name>
    <other_name>Clopidogrel</other_name>
    <other_name>Prasugrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age older than 18 years

          -  Scheduled for elective or ad-hos PCI

          -  Aspirin use daily for greater or equal to one week

          -  Aspirin resistant (ARU greater than or equal to 550 on Verify Now-ASA

        Exclusion Criteria:

          -  Pre-procedural elevation of cardiac biomarkers (CK-MB greater or equal to 10.4ng/dl
             or Tnl greater or equal to 0.4ng/dl

          -  administration of any GP IIb/IIIa inhibitor, anticoagulation or lytic therapy in the
             previous 30 days

          -  Ongoing bleeding or bleeding diathesis, contraindications for anticoagulation or
             increased bleeding risk or history of bleeding in the last eight weeks

          -  Previous stroke or transient ischemic attack or any intracranial pathology in the
             last six months, major surgery or trauma within the previous six weeks

          -  Platelet count less than hundred thousand per cubic millimeter or hematocrit &lt;33% or
             hemoglobin &lt;11 g per deciliter

          -  Subjects who received full dose low molecular weight heparin within six hours prior
             to randomization

          -  Allergy or intolerance to any of the study drugs or the presence of any serious
             comorbidity with life expectancy of â‰¤1year

          -  Scheduled for saphenous vein graft intervention, chronic total occlusions or with
             impaired renal function (eGFR&lt;60ml/min) or patients who were taking anticoagulants or
             antiplatelet agents other than aspirin and clopidogrel or nonsteroidal
             anti-inflammatory drugs within two weeks before the PCI procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annapoorna S Kini, MD MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 6, 2015</lastchanged_date>
  <firstreceived_date>April 12, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Adverse Cardiovascular Event</keyword>
  <keyword>MACE</keyword>
  <keyword>Death</keyword>
  <keyword>MI</keyword>
  <keyword>CK MB greater 3x Normal</keyword>
  <keyword>Urgent Revascularization</keyword>
  <keyword>Stent Thrombosis</keyword>
  <keyword>Bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Krestin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
